BuybackMay 4, 2026, 07:02 AM
Indivior Announces $175M Accelerated Share Repurchase
AI Summary
Indivior Pharmaceuticals, Inc. announced it has entered into a $175 million accelerated share repurchase (ASR) agreement with Barclays Bank PLC. This ASR is a component of the company's existing $400 million share repurchase program. Indivior made an upfront payment of $175 million and received an initial delivery of 3,717,473 shares, with final settlement anticipated by late June 2026. The company affirmed that the ASR is not expected to affect its previously issued financial guidance.
Key Highlights
- Entered into a $175 million accelerated share repurchase (ASR) agreement.
- The ASR is part of the company's previously announced $400 million share repurchase program.
- Made an upfront payment of $175 million to Barclays Bank PLC.
- Received an initial delivery of 3,717,473 shares.
- Final settlement of the ASR transaction is expected by June 22, 2026.
- Remaining $100 million under the share repurchase authorization for future repurchases.
- ASR is not expected to impact previously issued financial guidance.